Accelerated development of a potential treatment for cystic fibrosis

by | Oct 22, 2021

Sectors: Medical research, Pharmaceuticals

Industries: Biotechnology

Technology including intellectual property and knowhow, developed by the UK Gene Therapy Consortium, made up of researchers at Imperial College London, the University of Oxford and Edinburgh University has been licensed to Boehringer Ingelheim in a continuation of a licence agreement first announced in 2018.

Related technologies

A novel targeted drug delivery system

A novel targeted drug delivery system

Red blood cell-derived vesicles (RBCVs) for use in targeted delivery of thrombolytic drugs to blood clots. Find out more

Aptamer-based multiplex screening platform

Aptamer-based multiplex screening platform

A fully flexible, scalable and low-cost detection platform to sense multiple protein targets simultaneously by grafting specific sequences along the backbone of a double-stranded DNA carrier. Find out more

Charcot-Marie Tooth Disease model

Charcot-Marie Tooth Disease model

Proposed use Research into Charcot-Marie Tooth Disease (Type 1A). Research into autoimmune neurological disorders would be the main ... Find out more

Related news

Accelerated development of a potential treatment for cystic fibrosis

Accelerated development of a potential treatment for cystic fibrosis

The UK Cystic Fibrosis Gene Therapy Consortium (GTC) is one of the partners in a licensing agreement with Boehringer Ingelheim. Find out more

Sign up for updates

Sign up for monthly technology alerts via email, and find other ways to connect with us.

Loading...